12:00 AM
 | 
Jul 14, 2008
 |  BioCentury  |  Product Development

NeuroSearch TIPOs the scales

NeuroSearch A/S believes its tesofensine obesity therapeutic may provide greater efficacy than marketed drugs due to its long half-life and mechanism of action that involves inhibiting the reuptake of three monoamines - serotonin, dopamine and norepinephrine. Last week’s interim results from the TIPO-4 extension of the 24-week Phase IIb TIPO-1 trial bolster the company’s case, as it now has data showing tesofensine’s effects persist for at least an additional 24 weeks.

TIPO-1 was a double-blind trial in which 203 patients received 0.25, 0.5 or 1 mg doses of tesofensine or placebo. The average weight loss at 24 weeks in the low, medium and high-dose groups was 6.7, 11.3 and 12.8 kg vs. a loss of 2.2 kg for placebo (p<0.0001 for all).

The open-label Phase IIb TIPO-4 trial enrolled 140 patients who participated in TIPO-1. All patients in TIPO-4 were washed out for eight weeks before receiving 0.5 mg of tesofensine for 48 weeks. The interim 24-week results reported last week were from two sets of patients: those who received placebo in TIPO-1 and those who received 0.5 mg...

Read the full 877 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >